Toward a More Precise Future for Oncology. Academic Article uri icon

Overview

abstract

  • Prospective molecular characterization of cancer has enabled physicians to define the genomic changes of each patient's tumor in real time and select personalized therapies based on these detailed portraits. Despite the promise of such an approach, previously unrecognized biological and therapeutic complexity is emerging. Here, we synthesize lessons learned and discuss the steps required to extend the benefits of genome-driven oncology, including proposing strategies for improved drug design, more nuanced patient selection, and optimized use of available therapies. Finally, we suggest ways that next-generation genome-driven clinical trials can evolve to accelerate our understanding of cancer biology and improve patient outcomes.

publication date

  • April 13, 2020

Research

keywords

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Drug Development
  • Molecular Targeted Therapy
  • Neoplasms
  • Patient Selection

Identity

PubMed Central ID

  • PMC7499397

Scopus Document Identifier

  • 85082957793

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-1119-2580

PubMed ID

  • 32289268

Additional Document Info

volume

  • 37

issue

  • 4